Dublin, Sept. 13, 2017 -- The "Diabetes Insulin Pen Market Outlook 2022: Top 5 European Countries Opportunity and Demand Analysis, Market Forecast 2017 - 2022" report has been added to Research and Markets' offering.
Diabetes Insulin Pen Market Outlook 2022: Top 5 European Countries Opportunity and Demand Analysis, Market Forecast 2017-2022 examines the market, demand, competitive landscape and trends of the top 5 European markets of the insulin pen market. It provides an all-round analysis of overall number of patients with diabetes and insulin users. It offers information on users of insulin pens, specifically focusing on reusable and prefilled insulin pen users. Market outlook in value terms for the forecasted period for insulin pen market has been detailed in the report. The report also explores detailed description of growth drivers and barriers of the insulin pen market.
Market growth can be attributed to factors such as increasing number of patients with diabetes, high adoption rate, user-friendly design, surging popularity amid consumers, help avoid over/under-dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the field of insulin pen devices.
The report concludes with the profiles of major players in the insulin pen market such as Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford and Ypsomed. The major market players are evaluated on various parameters such as company overview, product outlook and latest development and trends of the insulin pen market.
Long-term Growth Projection and Development:
- Prefilled (Disposable) insulin pen grasps the dominant share in the top 5 European countries insulin pen market
- In 2016, there were over 7,800 Thousand users of insulin pen in the top 5 European countries
- Germany insulin pen market generated more than US$ 1.5 Billion in 2016
- Spain has shown its potential to become leading #2 market with around 20% market share in 2016
Top 5 European Countries Covered in the Report Have Studied from 8 Viewpoints:
1. Overall Diabetes Population (2011 - 2022)
2. Insulin Users (2011 - 2022)
3. Insulin Pen Users (2011 - 2022)
4. Reusable (Cartridge) Insulin Pen Users (2011 - 2022)
5. Prefilled (Disposable) Insulin Pen Users (2011 - 2022)
6. Insulin Pen Market (2011 - 2022)
7. Reusable (Cartridge) Insulin Pen Market (2011 - 2022)
8. Prefilled (Disposable) Insulin Pen Market (2011 - 2022)
Top 5 European Countries Covered in the Report are as follows:
1. United Kingdom
2. France
3. Italy
4. Spain
5. Germany
Key Companies Covered in the Report are as follows:
1. Novo Nordisk
2. Eli Lilly
3. Sanofi
4. Owen Mumford
5. Ypsomed
For more information about this report visit https://www.researchandmarkets.com/research/8jmzmh/diabetes_insulin
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diabetes Devices


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Apple Turns 50: From Garage Startup to AI Crossroads
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 



